Tafinlar (dabrafenib) — Medica
Thyroid Carcinoma, Differentiated
Initial criteria
- Patient has differentiated thyroid carcinoma (papillary, follicular, or oncocytic)
- Patient has recurrent or metastatic disease
- Patient has BRAF V600 mutation-positive disease
Approval duration
1 year